Literature DB >> 14504801

[Right portal vein ligation prior to extended right hemihepatectomy for synchronous colorectal liver metastases].

A H Hölscher1, K Schleimer, K T E Beckurts, H G Brochhagen, D L Stippel.   

Abstract

INTRODUCTION: A two-step procedure is suggested to reduce the overall operative risk in patients with colorectal cancer and large synchronous liver metastases, which demand an extended right hemihepatectomy for R0 resection.
METHODS: The clinical course and volumetric evaluation of the liver is described in three patients in whom preliminary ligation of the right branch of the portal vein was performed at the time of colon resection.
RESULTS: The size of the left lateral lobes increased by 9.9%, 13.7%, and 4.9% of total liver volume, respectively. At the same time, the noninfiltrated part of the right lobes shrunk by 36.7%, 36%, and 6% ukereas metastatic growth was 26.8%, 22.3%, and 12%. After 7 weeks, extended right hemihepatectomy could be performed in all three patients without signs of hepatic insufficiency, yielding R0 resection.
CONCLUSION: Can reduce the risk for extended right hemihepatectomy in selected patients with synchronous colorectal liver metastases.

Entities:  

Mesh:

Year:  2003        PMID: 14504801     DOI: 10.1007/s00104-003-0697-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  31 in total

1.  Application of preoperative portal vein embolization before major hepatic resection in patients with normal or abnormal liver parenchyma.

Authors:  Hisao Wakabayashi; Ken Ishimura; Keiichi Okano; Yukihiko Karasawa; Fuminori Goda; Takashi Maeba; Hajime Maeta
Journal:  Surgery       Date:  2002-01       Impact factor: 3.982

2.  Portal branch ligation in the rat. Reevaluation of a model.

Authors:  J Rozga; B Jeppsson; S Bengmark
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

3.  [Surgical resection of colorectal liver metastases: Gold standard for solitary and radically resectable lesions].

Authors:  J Scheele; A Altendorf-Hofmann; R Stangl; K Schmidt
Journal:  Swiss Surg       Date:  1996

4.  [Multistage liver resections in colorectal liver metastases. The Paul Brousse concept].

Authors:  D Azoulay; R Adam; D Castaing; E Savier; L A Veilhan; H Bismuth
Journal:  Chirurg       Date:  2001-07       Impact factor: 0.955

5.  Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors.

Authors:  R Adam; A Laurent; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

6.  Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.

Authors:  K Shirabe; M Shimada; T Gion; H Hasegawa; K Takenaka; T Utsunomiya; K Sugimachi
Journal:  J Am Coll Surg       Date:  1999-03       Impact factor: 6.113

7.  Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes.

Authors:  Eduardo de Santibañes; Fernando Bonadeo Lassalle; Lucas McCormack; Juan Pekolj; Guillermo Ojea Quintana; Carlos Vaccaro; Mario Benati
Journal:  J Am Coll Surg       Date:  2002-08       Impact factor: 6.113

8.  Evaluation of hepatocyte injury following partial ligation of the left portal vein.

Authors:  M Bilodeau; M C Aubry; R Houle; P N Burnes; C Ethier
Journal:  J Hepatol       Date:  1999-01       Impact factor: 25.083

9.  Portal vein embolization before right hepatectomy: prospective clinical trial.

Authors:  Olivier Farges; Jacques Belghiti; Reza Kianmanesh; Jean Marc Regimbeau; Roberto Santoro; Valérie Vilgrain; Alban Denys; Alain Sauvanet
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

10.  Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant.

Authors:  Dieter C Broering; Christian Hillert; Gerrit Krupski; Lutz Fischer; Lars Mueller; Eike G Achilles; Jan Schulte am Esch; Xavier Rogiers
Journal:  J Gastrointest Surg       Date:  2002 Nov-Dec       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.